Menu
10.9.2026 10:20:22 CEST | Thor Medical ASA | Managers' transaction
Oslo, Norway, 10 September 2026: Reference is made to the stock exchange announcements by Thor Medical ASA (the "Company") on 3 September 2026 regarding the successful completion of a private placement (the "Private Placement") and a retail offering through Nordnet (the "Retail Offering").
Reference is also made to the share lending agreement entered into by and between the Company, its shareholder Scatec Innovation AS as share lender and Arctic Securities AS and ABG Sundal Collier ASA as managers (the "Managers"), to facilitate delivery-versus-payment settlement in the Private Placement and the Retail Offering (the "Share Lending Agreement").
Following the registration of the share capital increases pertaining to the Private Placement and the Retail Offering, the Managers will today redeliver 57,291,667 new shares in the Company to Scatec Innovation AS pursuant to the Share Lending Agreement.
Scatec Innovation AS is a close associate of chairman John Andersen. Primary insider notifications pursuant to the EU Market Abuse Regulation article 19 are attached.
This announcement is subject to disclosure requirements pursuant to the EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act section 5-12.
Contacts
Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05 724, mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the radiopharmaceutical industry. The Company's proprietary production platform combines advanced separation technology with industrial-scale manufacturing capacity to deliver a reliable, scalable and cost-efficient supply of alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical companies from early-stage development to commercialization enabling scale-up of next-generation targeted cancer therapies. Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's production process requires neither irradiation nor nuclear reactors, providing significant cost advantages while minimizing radioactive waste. Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by powering the next generation of precision cancer treatment with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com.
